The present invention relates to particles comprising a core, in particular a magnetic core, and a first coating of a first shell material, wherein a second coating of a second shell material is applied to the surface of the first coating facing away from the core, the second shell material is different from the first shell material and has a higher refractive index than the first shell material.

The present invention relates to particles comprising a core, in particular a magnetic core, and a first coating of a first shell material, wherein a second coating of a second shell material is applied to the surface of the first coating facing away from the core, the second shell material is different from the first shell material and has a higher refractive index than the first shell material.

A biocompatible composite material for controlled release is disclosed, comprising a biocompatible metal oxide structure with a loaded network of pores. The pore network of the biocompatible composite material is filled with a uniformly distributed biologically active micellizing amphiphilic molecule, the size of these pores ranging from about 0.5 to about 100 nanometers. The material is characterized in that when exposed to phosphate-buffered saline (PBS), the controlled release of the active amphiphilic molecule is predominantly diffusion-driven over time.

A biocompatible composite material for controlled release is disclosed, comprising a biocompatible metal oxide structure with a loaded network of pores. The pore network of the biocompatible composite material is filled with a uniformly distributed biologically active micellizing amphiphilic molecule, the size of these pores ranging from about 0.5 to about 100 nanometers. The material is characterized in that when exposed to phosphate-buffered saline (PBS), the controlled release of the active amphiphilic molecule is predominantly diffusion-driven over time.

Addition-fragmentation oligomers of the general formula Z—B.sub.y-A-(B-A).sub.x-B-A-B.sub.y—Z, where the A monomers units are derived from a diester or diacid, the B monomer units are derived from a difunctional monomer having functional groups co-reactive with the acid or ester groups of the A monomer, x+y is zero to 60, Z comprises an ethylenically unsaturated, polymerizable group, A monomers comprise a 1-methylene-3,3-dimethylpropyl group, and at least one B monomer unit comprises a high refractive index group.

The present invention generally relates to the use of pre-formed bodies of Chemically Bonded Ceramics (CBCs) biomaterial for implantation purposes wherein the bodies are prepared ex vivo allowing process parameters to be optimized for desired long term properties of the resulting CBC biomaterial. More particularly, the pre-formed CBC material bodies of the present invention are sintered. The pre-formed body of CBC material is machined to the desired geometry and then implanted using a CBC cementation paste for fixation of the body to tissue. The invention also relates to a method of preparing pre-formed bodies of CBC biomaterial for implantation purposes, methods of preparing an implant thereof having desired geometry, and a method of implantation of the implant, as well as a kit for use in the method of implantation.

The present invention is directed to a process for producing a sintered lithium disilicate glass ceramic dental restoration out of a porous 3-dim article, the process comprising the step of sintering the porous 3-dim article having the shape of a dental restoration with an outer and inner surface to obtain a sintered lithium disilicate ceramic dental restoration, the sintered lithium disilicate glass ceramic dental restoration comprising Si oxide calculated as SiO2 from 55 to 80 wt.-%, Li oxide calculated as Li2O from 7 to 16 wt.-%, Al oxide calculated as Al2O3 from 1 to 5 wt.-%, and P oxide calculated as P2O5 from 1 to 5 wt.-%, wt.-% with respect to the weight of the dental restoration,
the sintering being done under reduced atmospheric pressure conditions, the reduced atmospheric pressure conditions being applied at a temperature above 600° C.

The present invention is also directed to a kit of parts comprising a porous 3-dim article having the shape of a dental milling block and a respective instruction of use.

The present invention is directed to a process for producing a sintered lithium disilicate glass ceramic dental restoration out of a porous 3-dim article, the process comprising the step of sintering the porous 3-dim article having the shape of a dental restoration with an outer and inner surface to obtain a sintered lithium disilicate ceramic dental restoration, the sintered lithium disilicate glass ceramic dental restoration comprising Si oxide calculated as SiO2 from 55 to 80 wt.-%, Li oxide calculated as Li2O from 7 to 16 wt.-%, Al oxide calculated as Al2O3 from 1 to 5 wt.-%, and P oxide calculated as P2O5 from 1 to 5 wt.-%, wt.-% with respect to the weight of the dental restoration,
the sintering being done under reduced atmospheric pressure conditions, the reduced atmospheric pressure conditions being applied at a temperature above 600° C.

The present invention is also directed to a kit of parts comprising a porous 3-dim article having the shape of a dental milling block and a respective instruction of use.

The present disclosure relates to a medical cement composition containing calcium silicate in an amount of less than 20 wt % of a total weight of the composition, with a lithium salt being added thereto. The medical cement composition of the present disclosure has a low compressive strength of 12 MPa or less, after being hardened, for easy removal, excellent stability in storage, and high bioactivity.

The present disclosure relates to a medical cement composition containing calcium silicate in an amount of less than 20 wt % of a total weight of the composition, with a lithium salt being added thereto. The medical cement composition of the present disclosure has a low compressive strength of 12 MPa or less, after being hardened, for easy removal, excellent stability in storage, and high bioactivity.